Skip to content
AnalystLens

West Pharmaceutical Services 8-K Report, Financial Results (Apr 24, 2025)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed April 24, 2025
Period End
April 24, 2025
Security
WST
In the record · 2016–202610-K1110-Q338-K118

WST filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Feb ’18Feb ’18
  2. Leadership change8-K · May ’20May ’20
  3. Leadership change8-K · Jul ’22Jul ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed April 24, 2025. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. (NYSE: WST) reported first-quarter 2025 net sales of $698.0 milliona, up 0.4%, with organic net sales growth of 2.1%.

Reported-diluted EPS was $1.23, compared to $1.55b in the same period last year, and adjusted-diluted EPS was $1.45, compared to $1.56. Net income was $89.8 million versus $115.3 million a year earlier. Operating profit declined to $107.0 million from $122.8 million, with the filing attributing the reported figures partly to restructuring and other charges of $17.8 million tied to its 2025 restructuring plan.

The company raised its full-year 2025 guidance. Net sales guidance was increased to $2.945 billion to $2.975 billionc from $2.875 billion to $2.905 billion, driven by favorable foreign currency movements, and adjusted-diluted EPS guidance was raised to $6.15 to $6.35 from $6.00 to $6.20. The adjusted EPS guidance incorporates an estimated $20 to $25 million in net tariff costs for the remainder of 2025.

Full-year capital spending guidance is unchanged at $275 milliond. Cash flow improved, with operating cash flow of $129.4 million and free cash flow of $58.1 million, compared with $27.6 million a year earlier. During the quarter the company repurchased 550,281 shares for $133.5 million, and it declared a third-quarter 2025 dividend of $0.21 per share, payable August 6, 2025.

02—Key points

Key Highlights

  1. Q1 2025 net sales of $698.0 million, up 0.4%; organic net sales growth of 2.1%.
  2. Reported-diluted EPS of $1.23 vs. $1.55 a year earlier; adjusted-diluted EPS of $1.45 vs. $1.56.
  3. Full-year 2025 net sales guidance raised to $2.945–$2.975 billion; adjusted-diluted EPS guidance raised to $6.15–$6.35.
  4. Adjusted EPS guidance includes an estimated $20–$25 million net impact from recently implemented tariffs for the rest of 2025.
  5. Free cash flow of $58.1 million vs. $27.6 million in Q1 2024; operating cash flow of $129.4 million.
  6. Repurchased 550,281 shares for $133.5 million at an average price of $242.63 during the quarter.
  7. Declared a third-quarter 2025 dividend of $0.21 per share, payable August 6, 2025.

03—Questions

Frequently Asked Questions

  1. Why did reported EPS fall while adjusted EPS declined less?

    Reported-diluted EPS of $1.23 included restructuring and other charges of $17.8 million in operating profit, which the company excludes in its adjusted measure. Adjusted-diluted EPS was $1.45 versus $1.56 a year earlier.

  2. What drove the raised net sales guidance?

    The company attributed the increase to favorable foreign currency movements. Its net sales guidance now includes an estimated full-year headwind of approximately $5.0 million, compared with a previous estimate of approximately $75 million.

  3. How is the company addressing tariffs?

    The adjusted-diluted EPS guidance incorporates an estimated $20 to $25 million for the net impact of recently implemented tariffs for the remainder of 2025. The filing states management is closely monitoring potential impacts and aims to react with offsetting mitigating measures.

  4. How did the segments perform?

    Proprietary Products net sales grew 0.6% to $563.0 million, with organic growth of 2.4%, and high-value products represented over 73% of segment net sales. Contract-Manufactured Products net sales declined 0.7% to $135.0 million, while organic net sales grew 0.8%.

04—Continue

← View all 8-K filings